Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 8/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283279 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL9470027 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL9637838 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL10043031 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25227184 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL1096268 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25077516 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL15070695 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL25227181 | 1.00 | USP2 (0.47) | USP2TLR2CETPCNR2CNR1 | |
| SCHEMBL3368533 | 0.99 | USP2 (0.45) | USP2TLR2CETPCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12521397-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-13 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12350274-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996015132-A1 | IMPROVED ANTIVIRAL PRODRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5187293-A | Blood platelet activating factor inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-4847376-A | COLORIMETRIC ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-07-11 | — | — | US | disclosed |
| EP-0147768-B1 | GLYCERIN DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-02-08 | — | — | EP | disclosed |
| US-4731373-A | BLOOD PLATELET ACTIVATING FACTOR | HOFFMAN-LA ROCHE INC. (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0094186-B1 | GLYCEROL DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1986-07-30 | — | — | EP | disclosed |
| US-4576933-A | Method of use of 1-(alkyl for alkylcarbanoyl)-2-carbamoylglycerol derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| EP-0147768-A2 | Glycerin derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-07-10 | — | — | EP | disclosed |
| EP-0094186-A1 | Glycerol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | USP2 3512/4885TLR2 500/4885CETP 974/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | USP2 1686/4885TLR2 1430/4885CETP 469/4885 |
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | USP2 2138/4885TLR2 2784/4885CETP 196/4885 |
| US-12350274-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | USP2 3422/4885TLR2 3556/4885CETP 4700/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | USP2 1637/4885TLR2 953/4885CETP 360/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | USP2 4298/4885TLR2 3182/4885CETP 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.